Avadel Pharmaceuticals (AVDL) Cash & Current Investments: 2009-2021
Historic Cash & Current Investments for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to $157.2 million.
- Avadel Pharmaceuticals' Cash & Current Investments fell 41.20% to $106.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $491.3 million, marking a year-over-year decrease of 39.37%. This contributed to the annual value of $157.2 million for FY2021, which is 28.99% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Cash & Current Investments stood at $157.2 million for FY2021, which was down 28.99% from $221.4 million recorded in FY2020.
- Over the past 5 years, Avadel Pharmaceuticals' Cash & Current Investments peaked at $221.4 million during FY2020, and registered a low of $64.2 million during FY2019.
- Moreover, its 3-year median value for Cash & Current Investments was $157.2 million (2021), whereas its average is $147.6 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first slumped by 38.99% in 2017, then soared by 245.09% in 2020.
- Over the past 5 years, Avadel Pharmaceuticals' Cash & Current Investments (Yearly) stood at $94.1 million in 2017, then increased by 6.21% to $99.9 million in 2018, then tumbled by 35.79% to $64.2 million in 2019, then surged by 245.09% to $221.4 million in 2020, then decreased by 28.99% to $157.2 million in 2021.